

# Ulrich Specks

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5534550/ulrich-specks-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

224  
papers

13,752  
citations

59  
h-index

112  
g-index

252  
ext. papers

16,733  
ext. citations

6.8  
avg, IF

6.12  
L-index

#	Paper	IF	Citations
224	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 834981	8.4	3
223	Vasculitis and Alveolar Hemorrhage <b>2022</b> , 341-357		
222	Association of COVID-19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis.. <i>Respirology Case Reports</i> , <b>2022</b> , 10, e0894	0.9	2
221	Predicting Kidney Response to Plasma Exchange in ANCA-Associated Vasculitis: Need for Plausible Models.. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2022</b> ,	12.7	2
220	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , <b>2022</b> , 11, e27273	2.1	
219	The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 1	6.2	0
218	Plasma exchange for the management of ANCA-associated vasculitis: the con position. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> , 36, 231-236	4.3	9
217	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , <b>2021</b> , 3, 404-412	3.5	4
216	Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Series. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> , 27, 64-72	1.1	1
215	Improvement of constrictive bronchiolitis (bronchiolitis obliterans) after rituximab therapy in 2 patients with primary sjögren syndrome. <i>Respiratory Medicine Case Reports</i> , <b>2021</b> , 33, 101432	1.2	0
214	Kidney Biopsy Chronicity Grading in Antineutrophil Cytoplasmic Antibody Associated Vasculitis. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> ,	4.3	3
213	Pleuritis and Pericarditis in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Chest</i> , <b>2021</b> , 160, 572-581	5.3	2
212	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 129, 114-118	2.2	2
211	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 114-118	2.2	2
210	Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum: reply. <i>Rheumatology</i> , <b>2020</b> , 59, 1187	3.9	
209	Lung involvement in ANCA-associated vasculitis. <i>Presse Medicale</i> , <b>2020</b> , 49, 104039	2.2	9
208	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1243-1249	2.4	22

207	International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> ,	10.2	13
206	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 622-631	59.2	211
205	Eosinophilic Granulomatosis With Polyangiitis: Clinical Predictors of Long-term Asthma Severity. <i>Chest</i> , <b>2020</b> , 157, 1086-1099	5.3	13
204	Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features. <i>American Journal of Pathology</i> , <b>2020</b> , 190, 1438-1448	5.8	4
203	Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	2
202	Chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis: clinical presentation and antineutrophil cytoplasmic antibodies. <i>International Forum of Allergy and Rhinology</i> , <b>2020</b> , 10, 217-222	6.3	4
201	Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. <i>Clinical Rheumatology</i> , <b>2020</b> , 39, 1581-1590	3.9	5
200	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102618	13.6	36
199	ANCA-associated vasculitis. <i>Nature Reviews Disease Primers</i> , <b>2020</b> , 6, 71	51.1	117
198	Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 2053	8.4	3
197	Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2020</b> , 31, 2688-2704	12.7	20
196	Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 519-530	6.2	5
195	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1001-1010	4.1	9
194	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35, 283-291	4.3	27
193	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 952-963	9.5	46
192	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 2170-2177	11.5	41
191	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1888-1893	9.5	19
190	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1879-1887	9.5	15

189	Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2019</b> , 30, 1123-1136	12.7	104
188	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 928-934	4.1	3
187	Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. <i>Nephrology Dialysis Transplantation</i> , <b>2019</b> , 34, 1508-1517	4.3	30
186	Update on the Management of Respiratory Manifestations of the Antineutrophil Cytoplasmic Antibodies-Associated Vasculitides. <i>Clinics in Chest Medicine</i> , <b>2019</b> , 40, 573-582	5.3	11
185	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Autoimmunity</i> , <b>2019</b> , 105, 102302	15.5	13
184	The Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1243	4.1	2
183	Remote Activation of a Latent Epitope in an Autoantigen Decoded With Simulated B-Factors. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2467	8.4	3
182	Remission maintenance in ANCA-associated vasculitis: does one size fit all?. <i>Expert Review of Clinical Immunology</i> , <b>2019</b> , 15, 1273-1286	5.1	
181	Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 117, 40-44	2.2	7
180	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 1114-1121	9.5	29
179	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. <i>Rheumatology</i> , <b>2018</b> , 57, 639-650	3.9	13
178	The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2018</b> , 13, 251-257	6.9	25
177	Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 597-606	6.4	44
176	Acquired cyclic neutropenia associated with cocaine-induced anti-neutrophil cytoplasmic antibodies binding to human neutrophil elastase. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E227-E229	7.1	1
175	Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. <i>Respiratory Medicine</i> , <b>2018</b> , 142, 66-72	4.6	11
174	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , <b>2018</b> , 13, e0205768	3.7	5
173	Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 2077-2086	9.5	7
172	Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis. <i>Clinical and Experimental Immunology</i> , <b>2017</b> , 188, 174-181	6.2	8

171	Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn. <i>Nephrology Dialysis Transplantation</i> , <b>2017</b> , 32, i37-i47	4.3	10
170	Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2017</b> , 18, 112	2.8	43
169	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1921-1932	59.2	416
168	Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. <i>Nephrology Dialysis Transplantation</i> , <b>2017</b> , 32, i139-i145	4.3	44
167	Reply. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1507-1508	9.5	
166	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1054-1066	9.5	85
165	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , <b>2017</b> , 100, 64-74	11	43
164	Current and Future Treatment Options for Eosinophilic Granulomatosis With Polyangiitis. <i>Current Treatment Options in Rheumatology</i> , <b>2017</b> , 3, 193-206	1.3	5
163	The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 2338-2350	9.5	74
162	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. <i>American Journal of Nephrology</i> , <b>2017</b> , 46, 231-238	4.6	10
161	Position paper: Revised 2017 international consensus on testing of ANCA in granulomatosis with polyangiitis and microscopic polyangiitis. <i>Nature Reviews Rheumatology</i> , <b>2017</b> , 13, 683-692	8.1	183
160	The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 169-175	9.5	17
159	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1004-1010	4.7	10
158	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 185-193	9.5	33
157	Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. <i>Journal of Renal Injury Prevention</i> , <b>2017</b> , 6, 18-25	1	19
156	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 103, 98-101	2.2	2
155	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , <b>2017</b> , 19, e50	7.6	15
154	Identification and phenotyping of circulating autoreactive proteinase 3-specific B cells in patients with PR3-ANCA associated vasculitis and healthy controls. <i>Journal of Autoimmunity</i> , <b>2017</b> , 84, 122-131	15.5	23

153	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 45, 475-82	5.3	73
152	Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 2945-2952	9.5	48
151	Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1700-10	9.5	86
150	Inhibitors and Antibody Fragments as Potential Anti-Inflammatory Therapeutics Targeting Neutrophil Proteinase 3 in Human Disease. <i>Pharmacological Reviews</i> , <b>2016</b> , 68, 603-30	22.5	21
149	Biopsy-proven pulmonary capillaritis: A retrospective study of aetiologies including an in-depth look at isolated pulmonary capillaritis. <i>Respirology</i> , <b>2016</b> , 21, 734-8	3.6	15
148	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1166-9	2.4	123
147	Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1467-76	9.5	61
146	Reply. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 2828-2829	9.5	
145	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. <i>Analytical Chemistry</i> , <b>2016</b> , 88, 6317-25	7.8	22
144	ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. <i>Nature Reviews Rheumatology</i> , <b>2016</b> , 12, 570-9	8.1	153
143	Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1922-32	9.5	86
142	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 545-53	3.9	254
141	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1209-12	4.1	50
140	Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis. <i>Journal of Autoimmunity</i> , <b>2015</b> , 59, 43-52	15.5	5
139	Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis?. <i>Current Opinion in Rheumatology</i> , <b>2015</b> , 27, 231-40	5.3	7
138	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 1081-2	4.3	1
137	Reply: Further Progress in Understanding Fibrosing Mediastinitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 192, 768	10.2	3
136	Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2015</b> , 26, 976-85	12.7	94

135	Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 535-44	9.5	18
134	Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>PLoS ONE</i> , <b>2015</b> , 10, e0121737	3.7	24
133	Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 1083-7	4.3	8
132	Isolated pauciimmune pulmonary capillaritis successfully treated with rituximab. <i>Chest</i> , <b>2015</b> , 147, e134-5	13.6	15
131	Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's). <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 428-32	9.5	19
130	Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2014</b> , 6, 58-74	3.8	8
129	An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1376-9	2.4	98
128	Treatment of ANCA-associated vasculitis: new therapies and a look at old entities. <i>Advances in Chronic Kidney Disease</i> , <b>2014</b> , 21, 182-93	4.7	6
127	Pituitary dysfunction in granulomatosis with polyangiitis: the Mayo Clinic experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 3988-94	5.6	50
126	Targeting B lymphocytes in progressive fibrosing mediastinitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 190, 1069-71	10.2	37
125	Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 301-10	4.7	36
124	Coexistent pulmonary granulomatosis with polyangiitis (Wegener granulomatosis) and Crohn disease. <i>American Journal of Surgical Pathology</i> , <b>2014</b> , 38, 354-9	6.7	14
123	Pathogenesis and Management of ANCA-Associated Vasculitis <b>2014</b> , 137-151		
122	Pulmonary Manifestations of Vasculitis <b>2014</b> , 123-137		
121	Efficacy of remission-induction regimens for ANCA-associated vasculitis. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 417-27	59.2	446
120	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1342-50	2.4	80
119	Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener's). <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 501-5	13.6	51
118	S1. Rituximab for ANCA-associated vasculitis: the experience in the United States. <i>Presse Medicale</i> , <b>2013</b> , 42, 530-2	2.2	5

117	Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2457-68		102
116	New features of disease after diagnosis in 6 forms of systemic vasculitis. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1905-12	4.1	29
115	Vasculitis: Refining phenotypes in ANCA-associated vasculitis. <i>Nature Reviews Nephrology</i> , <b>2013</b> , 9, 6-8	14.9	3
114	A monoclonal antibody (MCPR3-7) interfering with the activity of proteinase 3 by an allosteric mechanism. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 26635-48	5.4	15
113	urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 674-83	4.1	28
112	Biologic response modifiers for granulomatosis with polyangiitis (Wegener's): from promise to reality. <i>International Journal of Clinical Rheumatology</i> , <b>2013</b> , 8, 383-397	1.5	
111	Pneumocystis pneumonia in patients treated with rituximab. <i>Chest</i> , <b>2013</b> , 144, 258-265	5.3	120
110	Pulmonary necrotizing granulomas of unknown cause: clinical and pathologic analysis of 131 patients with completely resected nodules. <i>Chest</i> , <b>2013</b> , 144, 813-824	5.3	42
109	Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 273-9	4.7	34
108	Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 3770-8		199
107	Pulmonary Vasculitis and Hemorrhage <b>2012</b> , 722-730		
106	Pathogenesis of ANCA-associated vasculitis. <i>Current Rheumatology Reports</i> , <b>2012</b> , 14, 481-93	4.9	62
105	Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 3463-71		27
104	TNF- $\beta$ blocker therapy and solid malignancy risk in ANCA-associated vasculitis. <i>Current Rheumatology Reports</i> , <b>2012</b> , 14, 501-8	4.9	8
103	Update on diffuse alveolar hemorrhage and pulmonary vasculitis. <i>Immunology and Allergy Clinics of North America</i> , <b>2012</b> , 32, 587-600	3.3	61
102	Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis. <i>PLoS ONE</i> , <b>2012</b> , 7, e30197	3.7	14
101	Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. <i>Current Opinion in Rheumatology</i> , <b>2012</b> , 24, 15-23	5.3	33
100	Controversies in ANCA testing. <i>Cleveland Clinic Journal of Medicine</i> , <b>2012</b> , 79 Suppl 3, S7-11	2.8	9



99	Biologic agents in the treatment of granulomatosis with polyangiitis. <i>Cleveland Clinic Journal of Medicine</i> , <b>2012</b> , 79 Suppl 3, S50-3	2.8	6
98	Pulmonary Vasculitis <b>2012</b> , 365-386		0
97	Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. <i>Nephrology Dialysis Transplantation</i> , <b>2011</b> , 26, 2865-71	4.3	78
96	Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience. <i>Transplantation</i> , <b>2011</b> , 91, 1370-5	1.8	56
95	Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1777-81	4.7	49
94	Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 2495-503		50
93	Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 3988-97		48
92	Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 704	2.4	80
91	Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1048-54	4.1	35
90	IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 20736-41	11.5	58
89	Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial. <i>Open Arthritis Journal</i> , <b>2011</b> , 4, 1-18		17
88	Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 445-53	6.9	68
87	Accuracy of the ICD-9 code for identification of patients with Wegener's granulomatosis. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 474	4.1	8
86	Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 2188-98	6.9	186
85	Mapping of conformational epitopes on human proteinase 3, the autoantigen of Wegener's granulomatosis. <i>Journal of Immunology</i> , <b>2010</b> , 185, 387-99	5.3	25
84	Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen. <i>Journal of Autoimmunity</i> , <b>2010</b> , 35, 299-308	15.5	26
83	Rituximab versus cyclophosphamide for ANCA-associated vasculitis. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 221-32	59.2	1713
82	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1744-50	2.4	114

81	Alpha <sub>1</sub> -antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 3760-7		74
80	Successful pregnancy and delivery of a healthy newborn despite transplacental transfer of antimyeloperoxidase antibodies from a mother with microscopic polyangiitis. <i>American Journal of Kidney Diseases</i> , <b>2009</b> , 54, 542-5	7.4	44
79	Epitope-specific anti-neutrophil cytoplasmic antibodies: do they matter? Can they be detected?. <i>Apmis</i> , <b>2009</b> , 117, 63-6	3.4	4
78	ANCA-Associated Vasculitis <b>2009</b> , 245-267		
77	55-year-old man with purpura and foot pain. <i>Mayo Clinic Proceedings</i> , <b>2008</b> , 83, 93-6	6.4	
76	Idiopathic membranous nephropathy: diagnosis and treatment. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2008</b> , 3, 905-19	6.9	107
75	Response to Rituximab in membranous nephropathy. <i>Kidney International</i> , <b>2008</b> , 74, 392	9.9	
74	Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaine-induced midline destructive lesions. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1546-51		37
73	Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 2017-23	4.1	60
72	Targeting B lymphocytes as therapy for ANCA-associated vasculitis. <i>Rheumatic Disease Clinics of North America</i> , <b>2007</b> , 33, 741-54, v	2.4	10
71	Airway involvement in Wegener's granulomatosis. <i>Rheumatic Disease Clinics of North America</i> , <b>2007</b> , 33, 755-75, vi	2.4	60
70	Functional significance of Asn-linked glycosylation of proteinase 3 for enzymatic activity, processing, targeting, and recognition by anti-neutrophil cytoplasmic antibodies. <i>Journal of Biochemistry</i> , <b>2007</b> , 141, 101-12	3.1	13
69	Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. <i>Annals of Internal Medicine</i> , <b>2007</b> , 147, 611-9	8	181
68	Outcome of patients with small-vessel vasculitis admitted to a medical ICU. <i>Chest</i> , <b>2007</b> , 131, 972-6	5.3	51
67	ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. <i>American Journal of Medicine</i> , <b>2007</b> , 120, 643.e9-14	2.4	184
66	Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1027-31	4.1	19
65	The future of damage assessment in vasculitis. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1357-71	4.1	26
64	The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 2446-50	4.1	32

63	Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 1608-18		173
62	Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2006</b> , 173, 180-7	10.2	327
61	Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. <i>Cancer Research</i> , <b>2006</b> , 66, 4693-700	10.1	65
60	Subtle modifications of a PR3-ANCA ELISA affect assay performance. <i>Clinical Immunology</i> , <b>2006</b> , 118, 124-5	9	
59	Understanding cardiac troponin T in the newborn period. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2006</b> , 173, 816-7; author reply 817	10.2	4
58	BAFF is elevated in serum of patients with Wegener's granulomatosis. <i>Journal of Autoimmunity</i> , <b>2005</b> , 25, 298-302	15.5	122
57	Differences between human proteinase 3 and neutrophil elastase and their murine homologues are relevant for murine model experiments. <i>FEBS Letters</i> , <b>2005</b> , 579, 5305-12	3.8	45
56	Echocardiographic findings in patients with Wegener granulomatosis. <i>Mayo Clinic Proceedings</i> , <b>2005</b> , 80, 1435-40	6.4	58
55	Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. <i>Annals of Internal Medicine</i> , <b>2005</b> , 142, 620-6	8	225
54	A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases. <i>Journal of Immunological Methods</i> , <b>2005</b> , 307, 62-72	2.5	19
53	Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 262-8		355
52	A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 902-10		41
51	Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 2168-78		142
50	A 70-year-old man with pulmonary infiltrates and a positive antineutrophil cytoplasmic autoantibody test result. <i>Chest</i> , <b>2005</b> , 127, 1045-50	5.3	11
49	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 2488-95	4.1	28
48	Pulmonary capillaritis. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2004</b> , 25, 547-55	3.9	17
47	Wegener's granulomatosis presenting as multiple bilateral renal masses. <i>Nephrology Dialysis Transplantation</i> , <b>2004</b> , 19, 984-7	4.3	13
46	Tumor necrosis factor alpha blockade as therapy for sarcoidosis: comment on the article by Ulbricht et al. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 2717-8; author reply 2718-9		

45	Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 2954-65		150
44	Pulmonary involvement in Henoch-Schönlein purpura. <i>Mayo Clinic Proceedings</i> , <b>2004</b> , 79, 1151-7	6.4	28
43	Echocardiographic features of atrial myocarditis with giant cells: a case report. <i>Journal of the American Society of Echocardiography</i> , <b>2004</b> , 17, 1073-6	5.8	7
42	Pulmonary Involvement in Henoch-Schlein Purpura. <i>Mayo Clinic Proceedings</i> , <b>2004</b> , 79, 1151-1157	6.4	68
41	Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. <i>Blood</i> , <b>2004</b> , 104, 1411-8	2.2	192
40	Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. <i>Chest</i> , <b>2003</b> , 124, 177-85	3.5	311
39	Sinonasal Osteocartilaginous Necrosis in Cocaine Abusers: Experience in 25 Patients. <i>American Journal of Rhinology &amp; Allergy</i> , <b>2003</b> , 17, 33-43		56
38	Clinical utility of ANCA tests for the dermatologist. <i>International Journal of Dermatology</i> , <b>2003</b> , 42, 859-60	7	19
37	Effects of carboxy-terminal modifications of proteinase 3 (PR3) on the recognition by PR3-ANCA. <i>Kidney International</i> , <b>2003</b> , 63, 756-60	9.9	16
36	Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. <i>American Journal of Medicine</i> , <b>2003</b> , 115, 284-90	2.4	234
35	Different gender-associated genotype risks of Wegener's granulomatosis and microscopic polyangiitis. <i>Clinical Immunology</i> , <b>2003</b> , 109, 330-7	9	34
34	Does infection play a role in the pathogenesis of pulmonary vasculitis?. <i>Seminars in Respiratory Infections</i> , <b>2003</b> , 18, 17-22		26
33	Sinonasal osteocartilaginous necrosis in cocaine abusers: experience in 25 patients. <i>American Journal of Rhinology &amp; Allergy</i> , <b>2003</b> , 17, 33-43		12
32	Long-term follow-up of repair of external nasal deformities in patients with Wegener's granulomatosis. <i>Laryngoscope</i> , <b>2002</b> , 112, 731-7	3.6	29
31	Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. <i>Clinical Immunology</i> , <b>2002</b> , 103, 196-203	9	74
30	ANCA subsets: influence on disease phenotype. <i>Cleveland Clinic Journal of Medicine</i> , <b>2002</b> , 69 Suppl 2, SII56-9	2.8	6
29	Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 309-16	4.1	68
28	Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. <i>Arthritis and Rheumatism</i> , <b>2001</b> , 44, 463-8		44

27	A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). <i>Arthritis and Rheumatism</i> , <b>2001</b> , 44, 912-20		337
26	Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. <i>Arthritis and Rheumatism</i> , <b>2001</b> , 44, 2836-40		304
25	Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon. <i>Rheumatic Disease Clinics of North America</i> , <b>2001</b> , 27, 815-32, vii	2.4	22
24	Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis. <i>Medicine (United States)</i> , <b>2001</b> , 80, 391-404	1.8	97
23	Diffuse alveolar hemorrhage syndromes. <i>Current Opinion in Rheumatology</i> , <b>2001</b> , 13, 12-7	5.3	118
22	Are animal models of vasculitis suitable tools?. <i>Current Opinion in Rheumatology</i> , <b>2000</b> , 12, 11-9	5.3	17
21	Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. <i>Journal of Immunological Methods</i> , <b>2000</b> , 244, 117-31	2.5	21
20	What you should know about PR3-ANCA. Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCA. <i>Arthritis Research</i> , <b>2000</b> , 2, 263-7		21
19	Meningeal involvement in Wegener granulomatosis. <i>Mayo Clinic Proceedings</i> , <b>2000</b> , 75, 856-9	6.4	24
18	Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunocomplexes. <i>Journal of Immunological Methods</i> , <b>1998</b> , 211, 111-23	2.5	60
17	Antineutrophil cytoplasmic antibodies. <i>Arthritis and Rheumatism</i> , <b>1998</b> , 41, 1521-37		333
16	Cloning and functional expression of the murine homologue of proteinase 3: implications for the design of murine models of vasculitis. <i>FEBS Letters</i> , <b>1997</b> , 408, 187-90	3.8	35
15	Recombinant human proteinase 3, the Wegener's autoantigen, expressed in HMC-1 cells is enzymatically active and recognized by c-ANCA. <i>FEBS Letters</i> , <b>1996</b> , 390, 265-70	3.8	37
14	Microtiter plate immunoassay for the evaluation of platelet adhesion to fibronectin. <i>Journal of Immunological Methods</i> , <b>1996</b> , 191, 55-63	2.5	6
13	Immunohistochemical localization of collagen VI in diabetic glomeruli. <i>Kidney International</i> , <b>1994</b> , 45, 1648-56	9.9	46
12	Recombinant expression and properties of the Kunitz-type protease-inhibitor module from human type VI collagen alpha 3(VI) chain. <i>FEBS Journal</i> , <b>1994</b> , 225, 573-80		38
11	Cutaneous Wegener's granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients. <i>Journal of the American Academy of Dermatology</i> , <b>1994</b> , 31, 605-12	4.5	162
10	Anti-neutrophil cytoplasmic antibodies. <i>Mayo Clinic Proceedings</i> , <b>1994</b> , 69, 1197-8	6.4	41

9	Lesions of the respiratory tract associated with the finding of anti-neutrophil cytoplasmic autoantibodies with a perinuclear staining pattern. <i>Mayo Clinic Proceedings</i> , <b>1994</b> , 69, 819-24	6.4	16
8	Integrin and Arg-Gly-Asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI. <i>Experimental Cell Research</i> , <b>1993</b> , 206, 167-76	4.2	187
7	Expression of type VI collagen mRNA during wound healing. <i>Journal of Investigative Dermatology</i> , <b>1993</b> , 100, 329-34	4.3	53
6	Cell adhesion to type-VI collagen. <i>Biochemical Society Transactions</i> , <b>1991</b> , 19, 843-7	5.1	34
5	Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. <i>The American Review of Respiratory Disease</i> , <b>1990</b> , 141, 117-23		65
4	Clinical role of C-ANCA testing. <i>Clinical Immunology Newsletter</i> , <b>1990</b> , 10, 171-174		
3	Role of testing for anticytoplasmic autoantibodies in the differential diagnosis of scleritis and orbital pseudotumor. <i>Mayo Clinic Proceedings</i> , <b>1990</b> , 65, 1110-7	6.4	30
2	Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis. <i>Mayo Clinic Proceedings</i> , <b>1989</b> , 64, 28-36	6.4	216
1	Granulomatosis with Polyangiitis (Wegener's) 238-251		3